Pharmaceuticals and Social Media
BARRIE, ON, August 15th, 2012 – NewPharmaThinkers.com publishes an article from Lucy Fisher, Global Events Director at Eye for Pharma discussing social media in pharmaceuticals.
Social media is rising as an information channel for patients. According to eyeforpharma’
A recent Wall Street Journal article reported that Facebook has 845 million active monthly users and Google+ has 90 million registered users and has yet to fulfill on level of engagement. While Facebook users spent an average of six to seven hours per month on the site between September 2011 and January 2012, Google+ users only spent an average of three minutes per month during the same time period. Companies pulled away from Facebook in 2011 driven by the open log policy change.
In late 2011 at Health Canada, an expert committee made up of individuals in marketing, IT, regulatory and compliance, was formed to draft new guidelines. After extensive revision and consultation, Health Canada has reviewed the proposal and stated no objections to the code changes. In addition, a 16-page supplemental guideline was mainly authored by Deirdre Cozier of Sanofi Canada. As to execution of the new policies, this year in Canada, the PAAB will revise the “PAAB Code of Advertising Acceptance” and its guidelines for Online Activities, hopefully for implementation in January 2013.
One-third of pharmaceutical and medical device marketing digital experts cited Google+ as a channel to watch for the future, highlighting the channel’s more business friendly system. “It’s going to be a definite trend”, said a new media manager at a multinational pharma company.
Google+ appears to be on the road to success, with initial sign-ups in record numbers. Initial signups numbered over 10 million, even prior to the formal launch
Dr. Kors van Wyngaarden, Director Online Marketing and Global Integrated Communications for Philips points out that users are given a high level amount of control of what, when, how and with whom they share information with on the platform. This is likely to provide more confidence for users to more fully engage and share their information. Lastly, physician and patient communities may emerge in the future, and offer industry engagement opportunities.
Digital experts also stressed industry’s move away from a product centric sales strategy towards a value-added model for physicians and patients – working with them on disease education and communication. Digital experts said that future marketing initiatives should have this as a key driver. With the wide availability of information on the Internet and the speed with which it can be disseminated, digital experts said that transparency has become fundamental. Simon Björklund, Nordic Business Development Manager for Bioglan AB said, “The trend is definitely transparency and availability when you work with social media. The demands are fast answers and openness which also recently became inevitable with Facebook when they decided it would not be possible to turn off the log.” Manager with Merck, Fabrizio Caranci, said, “you cannot control everything. Patients now have the tools to discuss their disease”.
To view the original article, visit NewPharmaThinkers.com